Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT03115983

LimiFlex Clinical Trial for the Treatment of Degenerative Spondylolisthesis With Spinal Stenosis

The LimiFlex™ Clinical Trial is a prospective, concurrently controlled, multi-center study to evaluate the safety and effectiveness of decompression and stabilization with the Empirical Spine LimiFlex™ Paraspinous Tension Band compared to decompression and transforaminal lumbar interbody fusion (TLIF) with concomitant posterolateral fusion (PLF) for the treatment of lumbar degenerative spondylolisthesis (Grade I per Meyerding classification) with spinal stenosis. Clinical trial sites will enroll solely LimiFlex subjects or solely TLIF/PLF subjects.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

25 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sonoran Spine Research and Education Foundation, Tempe, Arizona, United States

Loading trial locations.

About this study

The LimiFlex™ Paraspinous Tension Band is a new stabilization option for patients being treated with surgical decompression for degenerative spondylolisthesis. The LimiFlex does not require pedicle screws to anchor to the spine; instead, two dynamic rods are attached to pedicle-sparing straps which encircle adjacent spinous processes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(patients must meet ALL of the following criteria to be eligible for participation in the study):

  • Lumbar degenerative spondylolisthesis (Grade I per Meyerding classification), at one level from L1 to S1, with radiographic confirmation using X-ray;

a. Grade I spondylolisthesis per Meyerding classification includes up to 25% anterior translation of a vertebra relative to the superior endplate of the subjacent vertebra at the index level. A patient is considered to have spondylolisthesis with a minimum 10% anterolisthesis at the affected level in a lateral x-ray image.

  • Lumbar spinal stenosis requiring decompression at up to two contiguous levels from L1 to S1, inclusive of the level diagnosed with degenerative spondylolisthesis, and confirmed radiographically using CT or MRI;

a. At the index level, lumbar spinal stenosis is at least moderate lumbar canal stenosis, defined as more than 25% reduction of the cross-sectional area compared with the next adjacent normal level, with nerve root crowding compared with the normal level, as determined by the investigator on CT Scan or MRI.

  • Neurogenic claudication or radiculopathy symptoms including leg pain, muscle weakness, and/or sensation abnormality, with or without back pain as evidenced by patient history;
  • Persistent symptoms despite at least 3 months of conservative treatment that may include but is not limited to physical therapy, medications, and/or epidural injections;
  • A pre-operative Visual Analog Scale (VAS) leg pain score of ≥50 on a 100 mm scale;
  • Leg pain includes hip and/or buttock pain on the same side
  • A pre-operative Oswestry Disability Index (ODI) score ≥35 points on a 100-point scale;
  • Candidate for surgical decompression at a single level or two contiguous levels, with stabilization at only one level between L1-S1;
  • Posterior element anatomy is appropriate for interspinous fixation including prediction of presence of spinous processes of segment to be instrumented following decompression (investigational AND control groups) and a prediction of >50% of facet joints present following decompression (investigational group only);
  • ≥25-80 years of age and skeletally mature;
  • Patient has the necessary mental capacity to participate and is willing and able to participate in the study for the duration of the study follow-up and is able to comply with study requirements; and
  • Patient is willing to provide Informed Consent for study participation.

Exclusion criteria

  • A primary and predominate diagnosis of discogenic back pain;
  • A primary and predominate diagnosis of facet-mediated back pain;
  • Back or non-radicular leg pain of unknown etiology;
  • Significant peripheral vascular disease causing vascular claudication;
  • Significant peripheral neuropathy caused by conditions other than spinal stenosis;
  • History of fixed or permanent neurological deficit related to spinal cord injury;
  • History of any previous surgery* at any level in the lumbosacral spine except for a discectomy or decompression;
  • History of any previous surgery* at the level planned for treatment;
  • previous surgery includes spinal stimulator placement but does NOT include epidural injections, rhizotomy or nerve ablation.
  • Isthmic spondylolisthesis or spondylolysis (pars fracture) at any level in the lumbar spine;
  • Clinically significant compromise of vertebrae at L1 to S1 levels due to osteoporotic vertebral compression fracture or any traumatic, neoplastic, metabolic or infectious pathology or congenital abnormality;
  • Spinous process fracture(s) or other posterior element fracture(s) of the segment to be instrumented that would preclude secure fixation of the LimiFlex Device to the spinous process;
  • Spinous process insufficiency or deformity that would preclude secure fixation of the LimiFlex Device to the spinous process including spinous process length <10 mm from lamina to dorsal tip or other significant deformity due to trauma, or congenital abnormality such as spina bifida occulta at the planned instrumented level that would preclude secure fixation of the LimiFlex Device to the spinous process;
  • The estimated distance between the LimiFlex Device strap attachment points (midpoint of the cranial edge of the cranial spinous process and the midpoint of the caudal edge of the caudal spinous process) is <30mm on pre-operative lateral standing radiographs at the segment to be instrumented;
  • Degenerative lumbar scoliosis with a Cobb angle >10° at the affected motion segment;
  • Symptomatic lumbar stenosis that is not amenable to a direct decompression
  • Anklyosed motion segment at the target operative level
  • Severe osteoporosis, defined as history of fragility fracture and DXA T-score <-2.5 or QCT T-score <80mg/cubic cm. History of a fragility fracture requires that a DXA scan or QCT scan is completed;
  • Planned hip or knee replacement surgery, severe osteoarthritis or other musculoskeletal pathology of the hip or leg that could preclude reliable patient self reporting assessment scales and/or that would likely progress to surgery during study period;
  • Documented allergy to titanium or polyethylene;
  • Active local or systemic infection;
  • Receiving immunosuppressive or long-term steroid therapy;
  • Known history of bone metabolic disorder, including Paget's disease, hyperparathyroidism, renal osteodystrophy, and osteomalacia;
  • Disease or condition that would preclude accurate clinical evaluation of the safety and effectiveness of the study treatment or any significant medical conditions which would place the patient at excessive risk for surgery, such as:
  • severe rheumatoid arthritis or other severe autoimmune disease
  • active hepatitis (viral or serum) or HIV positive
  • unstable cardiac disease
  • uncontrolled diabetes
  • renal failure
  • severe muscular, neural or vascular diseases that endanger the spinal column
  • cauda equina syndrome
  • severe neurologic disorders including paralysis
  • Morbid obesity defined as BMI >40;
  • Active malignancy or history of metastatic malignancy within the last five years;
  • Women who are pregnant or are interested in becoming pregnant within the study period;
  • Currently seeking or receiving worker's compensation for back pain or spinal condition;
  • Currently involved in spinal litigation that potentially is associated with secondary financial gain;
  • Current involvement in a study of another investigational product for similar purpose;
  • Demonstrates three or more Waddell's Signs of Inorganic Behavior;
  • Active treatment of a major psychiatric condition, such as major depression, anxiety disorder, bipolar disorder, schizophrenia, personality disorder, that could prevent accurate completion of self reporting assessment scales;
  • Current history (within 12 months) of substance abuse, including alcohol abuse; or
  • A prisoner.

Treatment and study plan

LimiFlex

Device

LimiFlex implantation at a single level after surgical decompression.

Other names: LimiFlex Paraspinous Tension Band

Fusion Instrumentation

Device

Titanium alloy top-loading, polyaxial pedicle screws and cylindrical, titanium alloy rod instrumentation using autograft and/or allograft bone (i.e., cancellous and/or corticocancellous bone only), and/or a synthetic bone graft extender that is on-label for these indications (i.e., decorticated posterolateral gutter only). The TLIF requires a single PEEK or Titanium TLIF cage cleared by FDA for this indication filled with autograft and/or allograft bone (i.e., cancellous and/or corticocancellous bone only).

Decompression

Procedure

Surgical decompression at one or two contiguous levels from L1 to S1.

Fusion

Procedure

Transforaminal lumbar interbody fusion (TLIF) with concomitant posterolateral fusion (PLF) at a single level after surgical decompression.

Primary outcomes

  1. Composite Clinical Success

    Time frame: 24 Months

    Individual success for patients in the investigational LimiFlex or control fusion arm is assessed with Composite Clinical Success (CCS) criteria. To be considered a success, a subject must demonstrate all of the following:

    • 15 point improvement in Oswestry Disability Index (100 point scale)
    • Absence of a new or worsening, persistent neurological deficit
    • Absence of additional surgical intervention
    • Absence of device integrity failures

Secondary outcomes

  1. Oswestry Disability Index (ODI)

    Time frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo

    Oswestry Disability Index (ODI)

  2. Neurological Status

    Time frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo

    Neurological Status

  3. Additional surgical interventions

    Time frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo

    Additional surgical interventions

  4. Absence of device integrity failures defined as device breakage, device separation or disassembly, or device dislocation

    Time frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo

    Absence of device integrity failures defined as device breakage, device separation or disassembly, or device dislocation

  5. Estimated blood loss

    Time frame: Procedure

    estimated blood loss and units of blood transfused

  6. Length of procedure

    Time frame: Procedure

    Length of procedure (skin to skin)

  7. Hospital stay

    Time frame: Immediately upon discharge

    Hospital stay

  8. Return to normal activities of daily living

    Time frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo

    Length of time for subject to return to his/her normal activities of daily living.

  9. Work status

    Time frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo

    Work status and days to return to work (as appropriate)

  10. Pain medication including narcotics usage

    Time frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo

    Medication use for pain, including narcotic, usage

  11. Visual analog scale (VAS) leg pain

    Time frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo

    Leg pain as measured on a Visual Analog Scale (VAS)

  12. Visual analog scale (VAS) back pain

    Time frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo

    Back pain as measured on a Visual Analog Scale (VAS)

  13. Zurich claudication questionnaire (ZCQ)

    Time frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo

    Zurich claudication questionnaire

  14. SF-12 Quality of Life survey

    Time frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo

    SF-12 Health Survey

  15. Patient satisfaction

    Time frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo

    Patient satisfaction questionnaire

  16. Radiographic fusion status

    Time frame: Both groups: 6 wks, 3 mo, 6 mo, 12 mo, 24 mo, 36 mo, 48 mo, 60 mo

    Radiographic fusion status

Sponsors and collaborators

Lead sponsor

Empirical Spine, Inc.

Industry

Collaborators

  • Biomedical Statistical Consulting
  • MCRA
  • Medical Metrics Diagnostics, Inc

Registry information

Official study title

A Concurrently Controlled Study of the LimiFlex™ Paraspinous Tension Band in the Treatment of Lumbar Degenerative Spondylolisthesis With Spinal Stenosis

Important dates

Study start
2017
Primary completion
2025
Study completion
2026
First posted
Apr 14, 2017
Registry last updated
Aug 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.